Skip to main content
Clinical Trials/NCT05732597
NCT05732597
Completed
Not Applicable

How to Decide Which COVID-19 Patient With Myocardial Infarction to Send to the Cath Lab? - A Case Series of COVID-19 Patients With Myocardial Infarction

Bulgarian Cardiac Institute1 site in 1 country26 target enrollmentNovember 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Myocardial Infarction
Sponsor
Bulgarian Cardiac Institute
Enrollment
26
Locations
1
Primary Endpoint
to find a clinical or laboratory parameter, that would help in distinguishing between COVID-19 patients with MI and IRA and those, who have no IRA
Status
Completed
Last Updated
last year

Overview

Brief Summary

The aim of this study was to find a clinical or laboratory parameter, that would help in distinguishing between COVID-19 patients with myocardial infarction (MI), who have an infarct-related artery (IRA) and therefore, require immediate revascularization, and those, who have no IRA.

Detailed Description

The coronavirus pandemic has hit the world with its vast contagiousness, high morbidity, and mortality Apart from the direct damage to the lung tissue, the corona virus infection is associated with multiple organ damage, including the heart. Emerging evidence reveals a direct correlation between COVID-19 and cardiovascular complications, such as heart failure, myocarditis, arrhythmias, conduction abnormalities and acute coronary syndromes. The SARS-CoV-2 infection can frequently induce coagulation abnormalities that are associated with cardiopulmonary deterioration and death as a possible complication in all patients, despite presence or absence of concomitant risk factors and diseases. In addition, many patients with severe COVID-19 undergo thromboembolic events, which seem to be related to this particular coagulopathy. One of the most unpleasant and life-threatening types of thromboembolism is the one involving the coronary circulation, thus causing a heart attack. Many additional problems arise due to this condition e.g., access to a Cath lab, exposure of additional medical personnel, more complications and increased mortality for the patients. Invasive angiography for COVID-19 patients is logistically challenging and, in some cases, there is no intervention target, since microcirculatory disease and thrombosis is common in this group. Therefore, the investigators studied in detail the case series of 10 patients referred for primary percutaneous coronary intervention (pPCI) for MI in our catheterization laboratory during the course of COVID-19 infection. And the investigators set themselves the purpose to evaluate if there are some factors or parameters that could predict the presence of an interventional target - infarct related artery (IRA), prior to catheterization, and to determine their sensitivity and specificity.

Registry
clinicaltrials.gov
Start Date
November 1, 2020
End Date
February 27, 2022
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Bulgarian Cardiac Institute
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Acute coronary syndrome (ACS)
  • COVID-19 infection

Exclusion Criteria

  • No combination of ACS and COVID-19 infection

Outcomes

Primary Outcomes

to find a clinical or laboratory parameter, that would help in distinguishing between COVID-19 patients with MI and IRA and those, who have no IRA

Time Frame: During the whole study

Study Sites (1)

Loading locations...

Similar Trials